Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01697345

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy

Sponsor: Creighton University

Conditions Breast Cancer Dyspareunia Sexual Health Quality of Life Vaginal Dryness

Interventions Testosterone

Updated 7 times since 2017 Last updated: Dec 18, 2013 Started: Feb 28, 2013 Primary completion: Apr 30, 2013 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01697345, this EARLY_PHASE1 trial focuses on Breast Cancer and Dyspareunia and remains completed. Sponsored by Creighton University, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Dec 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Dec 2021 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Feb 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Creighton University

Data source: Creighton University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Omaha, United States